Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5933682 | 0.82 | TDP1 (0.39) | TDP1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL14079232 | 0.82 | TDP1 (0.44) | TDP1 | |
| SCHEMBL24090520 | 0.79 | TDP1 (0.41) | TDP1 | |
| SCHEMBL19592229 | 0.77 | TDP1 (0.39) | TDP1 | |
| SCHEMBL2341156 | 0.75 | TDP1 (0.33) | TDP1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL14072954 | 0.75 | TDP1 (0.37) | TDP1ALDH1A1 | |
| SCHEMBL1332279 | 0.71 | — | — | |
| SCHEMBL2020 | 0.71 | — | — | |
| SCHEMBL23945217 | 0.69 | — | — | |
| SCHEMBL39184 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-11071784-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| WO-2021108023-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20200353076-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | SUTRO BIOPHARMA, INC. | 2020-11-12 | — | — | US | disclosed |
| WO-2019170860-A1 | OLIGONUCLEOTIDE-FUNCTIONALIZED HYDROPHOBIC POLYMER NANOPARTICLES | UNIVERSITE DE STRASBOURG (FR) | 2019-09-12 | — | — | WO | disclosed |
| US-9687448-B2 | Nucleic acid lipid particle formulations | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9630978-B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-7550559-B2 | Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080318957-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-7425576-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7416868-B2 | Polyene polyketides, processes for their production and their use as a pharmaceutical | THALLION PHARMACEUTICALS, INC. (CA) | 2008-08-26 | — | — | US | disclosed |
| US-7399749-B2 | Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-07-15 | — | — | US | disclosed |
| US-7375088-B2 | Polyene polyketides, processes for their production and their use as a pharmaceutical | THALLION PHARMACEUTICALS INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| US-7342041-B2 | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070275436-A1 | Polyene polyketides, processes for their production and their use as a pharmaceutical | ECOPIA BIOSCIENCES, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070142300-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | MERCK SHARP & DOHME LLC | 2007-06-21 | — | — | US | disclosed |
| US-7186747-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | TDP1 3930/4885ALDH1A1 3319/4885TSHR 645/4885 |
| US-20070142300-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SERPINB1, HAVCR2, HPN | TDP1 3348/4885ALDH1A1 1238/4885TSHR 4826/4885 |
| US-20200353076-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | FOLR2, FOLR1, FCGRT | TDP1 3230/4885ALDH1A1 3301/4885TSHR 48/4885 |
| US-20070275436-A1 | Polyene polyketides, processes for their production and their use as a pharmaceutical | IPMK, PANK3, PANK1 | TDP1 1322/4885ALDH1A1 4091/4885TSHR 4148/4885 |
| US-20080318957-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | TDP1 2111/4885ALDH1A1 4062/4885TSHR 4679/4885 |
| US-11071784-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | TDP1 1779/4885ALDH1A1 3151/4885TSHR 2733/4885 |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | TDP1 3019/4885ALDH1A1 2185/4885TSHR 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.